This study aimed to develop a method for the quantitative determination of active medicinal substances that are part of a combined analgesic tablet under the code name "Analfenon". We previously developed technology obtaining combined ternary tablets with a potential analgesic effect which contains metamizole sodium, drotoverin hydrochloride, diphenhydramine hydrochloride. The amount of metamizole sodium, drotaverine hydrochloride, diphenhydramine hydrochloride was analyzed by methods spectrophotometry and titrimetry. Using the developed technique, the content of metamizole sodium, drotoverin hydrochloride, diphenhydramine hydrochloride in 5 samples was determined. The results of the quantitative analysis were evaluated using the metrological analysis. The results showed that the active drugs contained in the tablet are within the limits specified in the normative technical document. The proposed methods for the analysis of analgesic combined tablets provide reliable and well reproducible results. The developed methods formed the basis of regulatory documentation for a new analgesic drug - Analfenon tablets.
Cite this article:
Kholida Yunusova, Sevara Ravshanova. Quantitative Analysis of Combined Analgetic Tablets. Research J. Pharm. and Tech. 2020; 13(12):5749-5753. doi: 10.5958/0974-360X.2020.01001.X
1. International Association for the Study of Pain: Unrelieved pain is a major global healthcare problem. Available from: URL: http://www.iasp-pain.org/AM/Template.cfm? Section=Home and Template=/CM/Content Display. Cfm and Content ID=2908.
2. Raffaeli W and Arnaudo E. Pain as a disease: An overview. Journal of Pain Research. 2017; 10: 2003-2008.
3. Breivik H et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European Journal of Pain 2006; 10: 287-333.
4. Bond M and Breivik H. Why pain control matters in a world full of killer diseases. Pain Clinical Updates. 2004; 12(4): 1-4.
5. Bair MJ et al. Depression and pain comorbidity: a literature review. Archives of Internal Medicine. 2003; 163(20): 2433-2445.
6. Yunusova KhM and Ravshanova SE. The investigation of technological and physico-chemical characteristics of active substances and their granulates for the development combined drug “Analfenon”. EPRA International Journal of Research and Development. 2020; 5(4): 34-37.
7. Ravshanova SE and Yunusova KhM. Effect of various binding agents on the quality of hard gelatin capsules "Analfenon". International Journal of All Research Writings. 2020; 1(10): 81-85.
8. Ravshanova SE and Yunusova KhM. Research research research tablet dissolution “Analfenon”. Journal "Internauka". 2019; 11(93): 29-31.
9. Vedantika Das et al. UV-Spectroscopic Estimation and Validation of Drotaverine Concentration in Bulk and Dosage Form. Asian Journal of Pharmaceutical Analysis. 2016; 6(3): 188-190.
10. Vijayalakshmi R and Anbazhagan S. Method Development and Validation for Simultaneous Estimation of Metamizole Sodium and Pitofenone HCl by a Stability Indicating RP-HPLC. Asian Journal of Research in Chemistry. 2011; 4(9): 1371-1377.
11. National Center for Biotechnology Information. PubChem Database. Dipyrone, CID=522325. Available from: URL: https://pubchem.ncbi.nlm.nih.gov/compound/Dipyrone (accessed on Mar. 21, 2020).
12. Abdellatef HE et al. Spectrophotometric and spectrodensitometric determination of paracetamol and drotaverine HCl in combination. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2007; 66(4-5): 1147-1151.
13. Parameswara Rao K, Rao MC. Spectrophotometric methods in the analysis of drugs in pure and dosage forms. International Journal of Chemical Science. 2016; 14(4): 2389-2396.
14. Sakiara KA et al. Spectrophotometric determination of dipyrone in pharmaceutical preparations by using chromotropic acid. Farmaco. 1999; 54(9): 629-635.
15. European Pharmacopeia (2007) Council of Europe: Strasbourg, Edition 6 and p 3308.
16. British Pharmacopoeia, Vol. I, 2004.